January 8, 2018 / 3:55 PM / Updated 8 minutes ago BRIEF-Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln Reuters Staff 
Jan 8 (Reuters) - Celgene Corp: * SEES PRELIMINARY Q4 REVLIMID SALES $2,188 MILLION 
* ORATION ANNOUNCES PRELIMINARY 2017 UNAUDITED RESULTS AND 2018 FINANCIAL GUIDANCE * SEES Q4 2017 ADJUSTED EARNINGS PER SHARE ABOUT $2.00 * SEES FY 2017 GAAP EARNINGS PER SHARE $3.64 TO $4.19 * SEES Q4 2017 GAAP LOSS PER SHARE $0.09 TO $+0.46 * SEES FY 2018 REVENUE UP 12 PERCENT 
* SEES FY 2018 REVENUE ABOUT $14.4 BILLION TO $14.8 BILLION * SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.70 TO $8.90 * SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION * SEES FY 2017 ADJUSTED EARNINGS PER SHARE ABOUT $7.44 
* Q4 REVENUE $3.5 BILLION VERSUS I/B/E/S VIEW $3.46 BILLION * SEES PRELIMINARY Q4 OTEZLA SALES $371 MILLION 
* FY2017 EARNINGS PER SHARE VIEW $7.34, REVENUE VIEW $12.98 BILLION -- THOMSON REUTERS I/B/E/S 
* FY2018 EARNINGS PER SHARE VIEW $8.71, REVENUE VIEW $14.83 BILLION -- THOMSON REUTERS I/B/E/S 
* Q4 EARNINGS PER SHARE VIEW $1.93, REVENUE VIEW $3.46 BILLION -- THOMSON REUTERS I/B/E/S 
* REAFFIRMING 2020 TOTAL REVENUE AND ADJUSTED DILUTED EPS FINANCIAL TARGETS 
* FULL YEAR 2017 GAAP OPERATING MARGIN IS EXPECTED TO BE ABOUT 36 PERCENT 
* CELGENE - ESTIMATED GAAP EARNINGS PER SHARE FOR QUARTER & YEAR ENDED DEC 31, 2017 INCLUDE ESTIMATED IMPACT OF ABOUT $800 MILLION-ABOUT $1,300 MILLION DUE TO TAX CUTS AND JOBS ACT 
* ‍BASED ON GAAP, EPS FOR FULL-YEAR 2018 IS EXPECTED TO BE IN RANGE OF $6.58 TO $6.95​ Source text for Eikon: Further company coverage: